Aligning with national efforts to modernise cancer diagnostics, with Andrew Newland

Rethinking prescription drug affordability, with Vinay Patel

An AI supercomputer and discovering next-gen brain disorder treatments, with Tarek Samad

On genomics, NGS, and doing much more good than bad, with Markus Vossman

Delivering the right behavioural ingredients for the moment, with Amy Bucher

AI for the planet, AI for life sciences – with Patrick Leung

On the future of AI in life sciences, with women at the helm

Unlocking the future of obesity treatment

On AI and computational support of biochemistry, with Alan Roth

Harnessing the cell's own degradation machinery, with Benedict Cross

How blood tests can inform cancer treatment decisions, with Craig Eagle

The NHS, system burden, and a transformation prescription, with Ruth Chambers

On CB1s as an alternative to GLP-1s, with Punit Dhillon

Thermo Fisher Scientific on the value of an integrated approach to drug development

Digital transformation as a third lever in the affordability debate, with Alfred Olivares

Towards a democratic era of medicine, with Simon Kohl

CDMOs: Their crucial role and how to select one, with Sigma Mostafa

On US drug shortages and compounding pharmacies, with Shawn Hodges

Bridging science and strategy: Medical Affairs at the heart of omnichannel engagement

Delving into the physics of cancer, with Lew Bender

On inflammation, heart health, and GLP-1 possibilities, with Sandeep Kulkarni

On digital twins in rare disease research, with Piet van der Graaf

Veeva Commercial Summit 25: On quality data foundations and industry AI adoption with Karl Goossens

Veeva Commercial Summit 2025: On Data harmonisation with Alexander Ulrich

The hot topics of digitisation, with Rob Verheul

ESMO25: On radiopharmaceutical possibilities in oncology, with Dr Ebrahim Delpassand

ESMO25: On allosteric modulation in oncology, with Michael Lahn

Ten years of innovation at Frontiers Health – Live from Berlin with Jessica DaMassa

Veeva Commercial Summit: On AI, content, and MLR Review with Emma Hyland

Working together to innovate on pragmatic clinical trials, with Rob DiCicco

ESMO25: Harnessing the innate and the adaptive immune response, with Dr Sandeep Reddy

ESMO25: On next-generation bispecifics, with Tadaaki Taniguchi

ESMO25: On partnerships between pharma and diagnostic developers, with Jane Li

Policy in Focus: Trump’s MFN deals, FDA vouchers, and the government shutdown

Biotech’s biggest challenge isn’t scientific, but political – with James Roosevelt Jr

ESMO25: Immuno-therapies and translational research in oncology, with Inge Marie Svane

ESMO25: The changing landscape of rare oncology, with Jan Kirsten

On targeted radiotherapeutics, with Marc Hedrick

ESMO25: Following the science to a cure, with Nancy Ghattas

Towards one, cohesive AI workflow: In conversation with Ilya Burkov

ESMO25: Acceleration, accessibility, and accuracy, with Barry Vucsko

ESMO25: Transforming the cancer immunotherapy field, with Poolbeg's Liam Tremble #esmo #oncology

ESMO25: On helping patients with high unmet need, with Roberto Vieira & Adrian Jubb #ESMO #cancer

ESMO25: The importance of personalisation, with Bayer’s Dr Nicoletta Brega and Christine Roth #ESMO

Collaborating on a connected platform journey, with Alexander Alex and Florian Schnappauf

ESMO25: On getting ahead of cancer, with J&J's Henar Hevia & Carolyn Sousa

ESMO 2025: ITM's Dr Andrew Cavey on next-gen RPTs #ESMO

ESMO25: Patient-centric oncological futures with Boehringer Ingelheim

Smoothing a contract pathway through uncertainty: In conversation with Neal Masia

FH25: On the future of health, with Frontiers Health Chairman Roberto Ascione

Bolstering CAR-T therapies by tackling CRS, with Teresa Whalen

Allosteric small molecule therapies in PD, with Gene Mack

FH25: Jessica DaMassa on hosting, hype, and health innovation

Agentic AI buoys all stakeholders in oncology, with Eron Kelly

Improving ROI on AI investments and data quality, with Dr Jay Anders

A different approach to obesity treatment, with Steffen-Sebastian Bolz

The importance of being disruption ready, with Brandon Pence

FH25: Commercialising Health Tech and Deeptech, with Pilar Fernández Hermida

Why Regeneron is giving away sequencing “for free”, with Alison Fenney

Agentic AI, culture shifts, and commercialisation today: Anthony Cilento post-Axtria Ignite 2025